Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29154301 | 0.98 | TDP1 (0.45) | TDP1L3MBTL1CASP6ATMALDH1A1 | |
| SCHEMBL28674613 | 0.92 | TDP1 (0.41) | TDP1L3MBTL1CASP6ATMALDH1A1 | |
| SCHEMBL21749965 | 0.87 | TDP1 (0.51) | TDP1L3MBTL1CASP6ATMALDH1A1 | |
| SCHEMBL29197041 | 0.85 | TDP1 (0.50) | TDP1L3MBTL1CASP6ATMALDH1A1 | |
| SCHEMBL288357 | 0.84 | TDP1 (0.43) | TDP1CASP6ATMALDH1A1HIF1A | |
| Zinc Ion SCHEMBL29154302 | 0.84 | ATM (0.43) | TDP1CASP6ATMALDH1A1HIF1A | |
| SCHEMBL1584382 | 0.84 | TDP1 (0.43) | TDP1L3MBTL1CASP6ATMALDH1A1 | |
| SCHEMBL9362952 | 0.84 | TDP1 (0.43) | TDP1L3MBTL1CASP6ATMALDH1A1 | |
| SCHEMBL1349352 | 0.83 | MAPK1 (0.51) | TDP1CASP6ATMALDH1A1HIF1A | |
| SCHEMBL1201983 | 0.82 | TDP1 (0.44) | TDP1L3MBTL1CASP6ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118281338-A | F & NO-containing material2Methyl benzoate electrolyte, lithium ion battery and preparation method thereof | 电子科技大学 | 2024-07-02 | — | — | CN | claimed |
| WO-2015075749-A1 | NOVEL PROCESSES FOR THE PREPARATION OF VEMURAFENIB | LAURUS LABS PRIVATE LIMITED (IN) | 2015-05-28 | — | — | WO | claimed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-5652233-A | CARBAPENICILLINS | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| US-5380719-A | Quinoxaline biphenyl angiotensin II inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| EP-0062659-A4 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES. | FMC CORP (US) | 1983-01-14 | — | — | EP | disclosed |
| EP-0062659-A1 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES | FMC Corporation (US) | 1982-10-20 | — | — | EP | disclosed |
| US-4339457-A | OF CYCLOPROPANECARBOXYLIC ACIDS, INSECTICIDES, MITICIDES | FMC CORPORATION (US) | 1982-07-13 | — | — | US | disclosed |
| WO-1982001368-A1 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES | FMC CORP (US) | 1982-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | TDP1 510/4885L3MBTL1 2916/4885CASP6 3351/4885 |
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | TDP1 1130/4885L3MBTL1 2303/4885CASP6 2925/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | TDP1 1294/4885L3MBTL1 1416/4885CASP6 1030/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | TDP1 1130/4885L3MBTL1 2303/4885CASP6 2925/4885 |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | TDP1 1696/4885L3MBTL1 989/4885CASP6 3082/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | TDP1 489/4885L3MBTL1 2973/4885CASP6 3301/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | TDP1 650/4885L3MBTL1 861/4885CASP6 3030/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | TDP1 2427/4885L3MBTL1 300/4885CASP6 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.